title: Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension.
abstract: Combined administration of inhaled nitric oxide and beraprost sodium resulted in a more intense decrease in pulmonary vascular resistance than nitric oxide given alone (mean -33% vs -45%, p <0.05), without serious systemic hypotension. Combined therapy with nitric oxide and beraprost sodium is highly desirable in treating primary and secondary pulmonary hypertension in children.
authors.affiliation: Department of Pediatrics, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Ichida
authors.forename: K
authors.initials: K
authors.lastname: Uese
authors.forename: S
authors.initials: S
authors.lastname: Tsubata
authors.forename: I
authors.initials: I
authors.lastname: Hashimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Hamamichi
authors.forename: K
authors.initials: K
authors.lastname: Fukahara
authors.forename: A
authors.initials: A
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Miyawaki
mesh_terms: D002648:Child; D002675:Child, Preschool; D000242:Cyclic AMP / Q000097:blood; D006152:Cyclic GMP / Q000097:blood; D004357:Drug Synergism; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007223:Infant; D008168:Lung / Q000187:drug effects / Q000502:physiology*; D009569:Nitric Oxide / Q000494:pharmacology*; D014655:Vascular Resistance; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D014665:Vasodilator Agents; D009569:Nitric Oxide; C048081:beraprost; D011464:Epoprostenol; D000242:Cyclic AMP; D006152:Cyclic GMP